KAKEN PHARMACEUTIAL CO., LTD. Logo

KAKEN PHARMACEUTIAL CO., LTD.

R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.

4521 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
文京区本駒込二丁目28番8号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kaken Pharmaceutical Co., Ltd. is an R&D-driven pharmaceutical company engaged in the research, development, manufacturing, and marketing of prescription drugs, medical devices, and agrochemicals. The company focuses on creating innovative treatments, particularly in the fields of orthopedics, dermatology, and surgery. Its main products include Artz, an anti-osteoarthritis agent, and Clenafin, a treatment for onychomycosis. Kaken Pharmaceutical also has operations in animal health and real estate. With a corporate philosophy centered on improving patients' quality of life, the company distributes its products both in Japan and internationally.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for KAKEN PHARMACEUTIAL CO., LTD. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-09 07:12
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.2 KB
2025-08-06 08:52
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.2 KB
2025-07-09 08:16
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.9 KB
2025-07-01 02:34
Regulatory News Service
臨時報告書
Japanese 28.2 KB
2025-06-26 03:41
Regulatory News Service
内部統制報告書-第105期(2024/04/01-2025/03/31)
Japanese 24.6 KB
2025-06-26 03:39
Regulatory News Service
確認書
Japanese 8.7 KB
2025-06-26 03:38
Annual Report
有価証券報告書-第105期(2024/04/01-2025/03/31)
Japanese 1.8 MB
2025-06-11 06:41
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.7 KB
2025-05-30 08:42
Regulatory News Service
臨時報告書
Japanese 84.4 KB
2025-05-14 05:01
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.3 KB
2025-04-10 04:16
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.5 KB
2025-03-12 02:56
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.1 KB
2024-12-26 07:35
Prospectus
有価証券届出書(参照方式)
Japanese 82.4 KB
2024-11-13 05:25
Regulatory News Service
確認書
Japanese 8.7 KB
2024-11-13 05:24
Interim Report
半期報告書-第105期(2024/04/01-2025/03/31)
Japanese 243.3 KB

Automate Your Workflow. Get a real-time feed of all KAKEN PHARMACEUTIAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for KAKEN PHARMACEUTIAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden LIPUM
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland LONN
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland MAB
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany N/A
Marinomed Biotech AG Logo
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria MARI
Matricelf Ltd. Logo
Develops personalized 3D neural implants from patient cells to treat spinal cord injuries.
Israel MTLF
MediciNova,Inc. Logo
Developing small-molecule drugs for neurology, respiratory, and liver diseases.
Japan 4875

Talk to a Data Expert

Have a question? We'll get back to you promptly.